论文信息 - Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients - 字舞流文

Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients

S. Jagannath | C. Cordon-Cardo | S. Almo | M. Merad | V. Simon | L. Mulder | O. Van Oekelen | S. Parekh | F. Krammer | K. Russo | A. Chari | S. Richard | J. Richter | L. Sanchez | H. Cho | D. Verina | B. Upadhyaya | R. Banu | A. Rossi | K. Srivastava | A. Wajnberg | R. Mendu | N. Lyttle | C. Gleason | M. Bermúdez-González | Adolfo Aleman | Sarita Agte | Katerina Kappes | D. Floda | A. Salimbangon | M. Saksena | W. Mendez | L. Sominsky | H. Alshammary | G. Cai | C. Cognigni | A. Firpo | G. Kleiner | A. Oostenink | A. Rooker | D. André | A. Shin | C. Rodriguez | K. Beach | K. David | A. Azad | Ariel Kogan Zajdman | Kseniya Serebryakova | D. A. R. M.C. G. A. H. C. K. D. A. G. N. W. L.C.F. R. Andre Azad Banu Bermúdez-González Cai Chari Ch | C. Rodríguez

[1] A. Walls,et al. Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement , 2021, bioRxiv.

[2] P. Shields,et al. COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer , 2021, Cancer Cell.

[3] K. Pradhan,et al. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer , 2021, Cancer Cell.

[4] S. Jagannath,et al. Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma , 2021, Cancer Cell.

[5] M. Hernán,et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study , 2021, The Lancet.

[6] Michael I. Mandel,et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel , 2021, The New England journal of medicine.

[7] M. Dimopoulos,et al. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment , 2021, Blood Cancer Journal.

[8] S. Jagannath,et al. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma , 2021, Cancer Cell.

[9] A. Addeo,et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer , 2021, Cancer Cell.

[10] K. Pradhan,et al. Seroconversion rates following COVID-19 vaccination among patients with cancer , 2021, Cancer Cell.